Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01450306 · ClinicalTrials.gov registry record · NA

Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics

A NA study of Specific Phobia, sponsored by Hartford Hospital.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT01450306 is a NA study of Specific Phobia that has completed, run by Hartford Hospital. The registered enrollment target is 20 participants, below the 197-participant average among 5 other Specific Phobia trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01450306, a NA study of Specific Phobia, has completed, sponsored by Hartford Hospital.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.

Conditions Studied

Interventions

  • DRUG Placebo
  • BEHAVIORAL Exposure therapy
  • DRUG D-cycloserine

Study Locations (1)

Connecticut

  • Institute of Living/Hartford Hospital - Hartford

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-07
Est. Completion 2011-12
Phase NA

Sponsor

Hartford Hospital

75 total trials

What the Registry Record Tells You About NCT01450306

The ClinicalTrials.gov registry entry for NCT01450306 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 5 other Specific Phobia trials with a reported enrollment target (90% lower). The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Specific Phobia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01450306 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT01450306 about?

NCT01450306 is a clinical study titled "Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics". The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.

What is the current status of trial NCT01450306?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2010-07. Estimated completion is 2011-12.

What conditions does trial NCT01450306 study?

This clinical trial studies the following conditions: Specific Phobia.

What interventions are being tested in trial NCT01450306?

The interventions under investigation include: Placebo (DRUG), Exposure therapy (BEHAVIORAL), D-cycloserine (DRUG).

Who is sponsoring clinical trial NCT01450306?

This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01450306 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Specific Phobia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.